SeaStar Medical Holding Corporation (ICU)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 |
| Operating profit | $m | -12 | -14 | ||||||
| Net profit | $m | -3 | -5 | -12 | -26 | -25 | -12 | -14 | - |
| EPS reported | $ | -0.59 | -3.91 | ||||||
| Operating cashflow per share | $ | -0.66 | -3.35 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.66 | -3.35 | ||||||
| Free cash flow | $m | -14 | -14 | ||||||
| Net debt | $m | -11 | -7 | ||||||
| Book value equity | $m | 10 | 4 | ||||||
| Book value per share | $ | 0.50 | 1.05 | ||||||
| Number of shares | m | 20.73 | 4.08 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 4.78 | 11.58 | ||||||
| P/S LTM | x | 40.32 | 29.05 | ||||||
| P/FCF LTM | x | -3.66 | -3.63 | ||||||
| EV/EBITDA LTM | x | -3.15 | -2.80 | ||||||
| EV/Sales LTM | x | 31.04 | 1.21 | ||||||
| Earnings Yield LTM | % | -24.42% | -1.05% | ||||||
| FCF Yield | % | -27.33% | -27.52% | ||||||
| Quality | |||||||||
| ROE | % | -116.65% | -162.75% | ||||||
| ROIC | % | -1.11% | -3.26% | ||||||
| Operating margin | % | -9.87% | -8.17% | ||||||
| Gross margin | % | +95.71% | +92.64% | ||||||
| FCF/Sales | % | -1102.0% | -799.36% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +814.07% | +1168.9% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -25.90 | - | ||||||
| Net Debt/EBITDA | x | 0.94 | 0.51 | ||||||
| EBIT/Net interest | x | -37.01 | -518.11 | ||||||
| Net debt/market cap | % | +1.06% | 0.00% | ||||||
| Net debt/Equity | x | -1.10 | -1.62 | ||||||
| Gross debt/equity | x | 0.05 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
SeaStar Medical Holding Corporation (ICU)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free